Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($1.85) earnings per share for the quarter, beating analysts' consensus estimates of ($2.92) by $1.07, Zacks reports.
Inhibrx Biosciences Stock Performance
Shares of INBX stock traded up $1.65 during mid-day trading on Wednesday, reaching $23.57. The stock had a trading volume of 83,745 shares, compared to its average volume of 104,819. The business's fifty day moving average is $18.74 and its 200-day moving average is $14.87. The firm has a market cap of $341.20 million, a price-to-earnings ratio of 0.20 and a beta of 0.24. Inhibrx Biosciences has a 1-year low of $10.81 and a 1-year high of $25.29. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 1.04.
Analysts Set New Price Targets
Separately, JMP Securities reissued a "market perform" rating on shares of Inhibrx Biosciences in a report on Thursday, May 15th.
Get Our Latest Stock Analysis on INBX
Hedge Funds Weigh In On Inhibrx Biosciences
A number of institutional investors have recently modified their holdings of INBX. Invesco Ltd. purchased a new position in shares of Inhibrx Biosciences during the 2nd quarter valued at about $193,000. Russell Investments Group Ltd. raised its stake in shares of Inhibrx Biosciences by 11.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 29,993 shares of the company's stock valued at $428,000 after buying an additional 2,963 shares during the last quarter. Finally, Strs Ohio purchased a new position in shares of Inhibrx Biosciences during the 1st quarter valued at about $27,000. Hedge funds and other institutional investors own 82.46% of the company's stock.
About Inhibrx Biosciences
(
Get Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inhibrx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.
While Inhibrx Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access